SEC Filing Summary: Celsion Corporation (10-K)
Business Context and Reporting Period
Company: Celsion Corporation (Note: Input metadata referenced "Imunon, Inc." but the filing text identifies the registrant as Celsion Corporation).
Reporting Period: Fiscal year ended September 30, 2003.
Business Overview: Celsion is a biotechnology company developing minimally invasive treatment systems using focused heat energy (thermotherapy) for cancer and Benign Prostatic Hyperplasia (BPH). The company has no current product revenues and is focused on clinical trials and regulatory approval.
- BPH 800 System: Submitted Premarket Approval (PMA) application to the FDA in March 2003; FDA accepted the submission as filed in August 2003. A distribution agreement with Boston Scientific was signed in January 2003.
- Breast Cancer System: Phase II clinical trials are underway using Adaptive Phased Array (APA) technology.
- ThermoDox: Heat-activated liposome technology for drug delivery; Phase I trials for prostate cancer began in May 2003.
- CRI: Heat-activated gene-based Cancer Repair Inhibitor in late-stage animal testing.
Key Financial Metrics
| Metric | Fiscal 2003 | Fiscal 2002 |
|---|---|---|
| Total Revenues | $0 | $0 |
| Net Loss | $(13,274,071) | $(9,751,082) |
| Net Loss Per Share (Basic/Diluted) | $(0.12) | $(0.12) |
| Research & Development Expenses | $8,178,680 | $5,004,687 |
| Selling, General & Admin Expenses | $5,125,769 | $4,833,005 |
| Cash and Cash Equivalents (End of Period) | $11,410,533 | $928,819 |
| Working Capital | $11,011,594 | $735,216 |
| Accumulated Deficit | $(57,278,383) | $(43,820,081) |
| Long-Term Debt | $0 | $0 |
Material Changes vs. Prior Period
- Liquidity Improvement: Cash balances increased significantly from $928,819 to $11.4 million, driven by private equity placements and an investment from Boston Scientific.
- Increased Operating Loss: Net loss widened by approximately $3.5 million (36%) due to higher R&D and SG&A expenses.
- R&D Spike: R&D expenses rose 63% to $8.2 million. A significant portion ($2.175 million) was a non-cash payment to Duke University via stock issuance for license milestones.
- Capital Structure: All Series A and Series B Convertible Preferred Stock was converted to Common Stock during the fiscal year.
- Strategic Partnership: Entered a Distribution and Transaction Agreement with Boston Scientific, receiving $5 million in initial equity investment.
Guidance, Outlook, and Risks
Outlook: Management expects to continue incurring significant operating losses for the foreseeable future. The company anticipates expending approximately $10 million in fiscal 2004 for clinical testing and overhead. Current cash resources are deemed sufficient to fund operations through September 30, 2004.
Key Risks:
- Regulatory Approval: No assurance that the BPH 800 system or other products will receive FDA approval or that approval will be timely.
- Funding Requirements: The company has no committed sources of financing beyond current cash and will require additional equity or debt financing to continue operations post-2004.
- License Dependencies: Business relies on exclusive licenses from MIT, Duke, Sloan-Kettering, and MMTC. Failure to meet milestones could result in loss of rights.
- Market Acceptance: Microwave heat therapy has not been widely accepted in the U.S. medical community; reimbursement codes are critical for commercial success.
- Delisting Risk: Due to sustained losses and low stock price, the company faces potential delisting from The American Stock Exchange.
Investor Verification Checklist
- FDA Status: Verify the current status of the BPH 800 PMA application and any FDA requests for additional data.
- Cash Runway: Confirm if the $10 million burn rate estimate for fiscal 2004 remains accurate and if new funding has been secured.
- Boston Scientific Milestones: Review the specific milestones required to trigger the additional $10 million investment from Boston Scientific.
- License Compliance: Assess the company's progress against the regulatory and testing milestones required by its license agreements with Duke, MIT, and Sloan-Kettering.
- Reimbursement Codes: Check for updates on the assignment of Current Procedural Terminology (CPT) codes for breast cancer treatment and BPH therapy.